Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. LXEO
LXEO logo

LXEO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Lexeo Therapeutics Inc (LXEO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
4.370
1 Day change
-8.58%
52 Week Range
10.990
Analysis Updated At
2026/06/05
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

LXEO is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading below key near-term resistance with a bearish technical setup, no positive news catalyst, insider selling has accelerated, and there is no supportive institutional or congressional buying signal. Even though options sentiment is mildly bullish on the surface, the overall setup does not justify an aggressive entry for an impatient investor.

Technical Analysis

The current pre-market price is 4.78, which sits below the pivot level at 4.918 and well below resistance at 5.298. Momentum is weak: MACD histogram is negative at -0.0273, RSI_6 is 42.936, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. This indicates the stock remains in a downtrend rather than forming a reliable breakout. The provided pattern analysis also projects modest near-term downside probability over the next day, week, and month.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is mildly bullish by open interest, with a put-call ratio of 0.49, but the volume put-call ratio of 0.0 is too thin to confirm active bullish conviction. Implied volatility is extremely high at 436.15, with IV percentile at 95.63 and IV rank at 65.03, suggesting expensive options pricing and elevated uncertainty rather than a clean directional setup. Open interest is also modest, so this is not a strong options-backed buy signal.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
11
Buy
3

Positive Catalysts

  • No recent news was reported in the last week, so there are no clear event-driven catalysts. The only mildly constructive factor is that options open interest leans slightly bullish, but this is weak compared with the broader technical and flow picture.

Neutral/Negative Catalysts

  • Insiders are selling, and the selling amount has increased 271.82% over the last month, which is a clear negative. Hedge funds are neutral with no significant trading trends over the last quarter. There is no recent news catalyst, no AI Stock Picker signal, no SwingMax signal, and no congress trading activity to support accumulation.

Financial Performance

No usable financial snapshot was provided due to an error, so latest-quarter revenue and earnings trends cannot be assessed from the dataset. Because the latest quarter season is unavailable, there is no financial-growth evidence here to support a long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided in the dataset, so there is no evidence of recent Wall Street upgrades or target increases. Based on the available information, the Wall Street view appears cautious to negative rather than bullish, since there is no analyst support, no positive catalyst, and insiders are actively selling.

Wall Street analysts forecast LXEO stock price to rise
7 Analyst Rating
Wall Street analysts forecast LXEO stock price to rise
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.780
sliders
Low
13
Averages
20.29
High
30
Current: 4.780
sliders
Low
13
Averages
20.29
High
30
Raymond James
initiated
$25
AI Analysis
2025-12-17
Reason
Raymond James
Price Target
$25
AI Analysis
2025-12-17
initiated
Reason
Raymond James initiated coverage of Lexeo Therapeutics with a Strong Buy rating and $25 price target. Based on strong results from two Phase 1/2 clinical trials and constructive feedback from FDA, Lexeo's lead asset LX2006 for cardiomyopathy associated with Friedreich's Ataxia is "well-positioned for success" in its pivotal trial, the analyst argues. The firm anticipates the stock will move next year on a finalized pivotal protocol with FDA and initial proof of concept data on a second, unmodeled gene therapy asset, LX2020, notes the analyst, who models LX2006 revenue of $14.1M in FY27 and growing to $805.3M in FY32.
Cantor Fitzgerald
NULL -> Overweight
initiated
$19
2025-11-20
Reason
Cantor Fitzgerald
Price Target
$19
2025-11-20
initiated
NULL -> Overweight
Reason
Cantor Fitzgerald initiated coverage of Lexeo Therapeutics with an Overweight rating and $19 price target.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for LXEO
Unlock Now

People Also Watch